Author

A. Riera

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Biophysics· 1 Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:differential expression· 1 Organism:human· 1

Frequent Co-Authors

C. Sanchez-Zarzalejo· 2 shared A. Banuelos· 1 shared A. Escobedo· 1 shared A. Henriques· 1 shared A. Ruffoni· 1 shared B. Mateos· 1 shared C. Batlle· 1 shared C. Garcia-Cabau· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

C. Sanchez-Zarzalejo

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in mice

D. V. F. Tauriello, E. Sancho, D. Byrom, C. Sanchez-Zarzalejo, M. Salvany, A. Henriques, S. Palomo-Ponce, M. Sevillano, X. Hernando-Momblona, J. A. Matarin, I. Ramos, I. Ruano, N. Prats, E. Batlle, A. Riera

This paper describes the development of HYL001, a TGFβ inhibitor that effectively combats microsatellite stable CRC metastasis in mice when combined with immune checkpoint therapy.

bioRxiv · May 10, 2024 · PreprintPharmacology & Toxicology

Rational optimization of a transcription factor activation domain inhibitor

S. Basu, P. Martinez-Cristobal, M. Pesarrodona, M. Frigole-Vivas, E. Szulc, M. Lewis, A. Banuelos, C. Sanchez-Zarzalejo, S. Bielskute, J. Zhu, K. Pombo-Garcia, C. Garcia-Cabau, C. Batlle, B. Mateos, M. Biesaga, , X. Salvatella

This study optimizes a small molecule inhibitor targeting the aromatic-rich activation domain of the androgen receptor, showing improved affinity and antitumorigenic effects in prostate cancer models.

bioRxiv · Aug 18, 2022Biochemistry

Somatostatin, an In Vivo Binder to Aβ Oligomers, Binds to βPFOAβ(1-42) Tetramer

E. Puig, J. Tolchard, A. Riera, N. Carulla

This study shows that somatostatin binds specifically to the βPFOAβ(1-42) tetramer but not monomeric Aβ(1-42), providing insights into its role in the amyloid cascade and AD.

bioRxiv · May 11, 2020Biophysics

Design, optimization and validation of genes commonly used in expression studies on DMH/AOM rat colon carcinogenesis model

D. Bars-Cortina, A. Riera, G. Gou, M. C. Pinol-Felis, M.-J. Motilva

The paper designs, optimizes, and validates qPCR primers for 17 genes and two reference genes in a DMH/AOM rat CRC model to improve reproducibility of mRNA expression studies.

bioRxiv · Jul 9, 2018Cancer Biology